USANA Health Sciences, Inc.

As of June 30, 2026, USANA Health Sciences, Inc. carries a market capitalization of 394.19M, placing it among publicly traded companies globally. Its enterprise value stands at 270.29M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

USANA Health Sciences, Inc.'s next confirmed earnings release is scheduled for November 3, 2026.

As of June 30, 2026, USANA Health Sciences, Inc. has 18.46M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.43, and the price-to-book ratio stands at 0.75.

As of June 30, 2026, USANA Health Sciences, Inc. trades at an EV/EBITDA multiple of 7.16 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.30 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. USANA Health Sciences, Inc. trades at an EV/FCF ratio of 24.17, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 270.29M versus a market cap of 394.19M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, USANA Health Sciences, Inc. maintains a current ratio of 2.66, meaning it holds 2.7x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, USANA Health Sciences, Inc. posted a negative return on equity (ROE) of -4.30, meaning shareholder capital produced losses rather than profits. Return on invested capital (ROIC) comes in at 2.15 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) is negative at -3.16, reflecting losses generated across the asset base. Return on capital employed (ROCE) is negative at -3.62, pointing to unprofitable operations over the period. The company generates approximately 569,960.06 in revenue per employee across its workforce of 1,602.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.43 indicates how many times USANA Health Sciences, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, USANA Health Sciences, Inc. recorded 31.79M in income tax expense. That works out to an effective tax rate of 1,253.35, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 2.54M, leaving -22.72M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, USANA Health Sciences, Inc.'s stock has declined approximately 30.56% over the past 52 weeks. The 50-day moving average sits at 14.44, while the 200-day moving average is 18.28.

Over the twelve months ended June 30, 2026, USANA Health Sciences, Inc. generated 913.36M in revenue and converted that into -22.72M in net income, yielding earnings per share of -1.59. EBITDA reached 37.73M, while operating income came in at 41.49M.

These figures are as of June 30, 2026. Total book value stands at 526.31M, with working capital of 175.39M providing operational flexibility.

USANA Health Sciences, Inc. produced 27.73M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -11.79M in capital expenditures, free cash flow totaled 15.93M - equivalent to 0.87 per share.

Over the twelve months ended June 30, 2026, USANA Health Sciences, Inc. posted a gross margin of 77.45, reflecting its pricing power and cost economics. The operating margin of 4.54 and net profit margin of -2.49 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 4.06, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 1.32, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to USANA Health Sciences, Inc. shareholders.

USANA Health Sciences, Inc.'s most recent stock split took place on November 23, 2016 with a 1:2 split ratio.

As of June 30, 2026, USANA Health Sciences, Inc. has an Altman Z-Score of 5.82, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.